Evidence map›Paper›PMID 42106020›Full record

ArticleGenetics research2026

HRD-Driven Reprogramming of Macrophage Function and Spatial Architecture in High-Grade Serous Ovarian Cancer.

Hua Lan, Fang Xu, Linshuang Li, Xin Wei, Minghua Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genetics research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Hua LanDepartment of Gynecology and Obstetrics, Changsha Central Hospital of University of South China, Changsha, Hunan, China.ORCID 0009-0006-0258-1648
Fang XuDepartment of Gynecology and Obstetrics, Changsha Central Hospital of University of South China, Changsha, Hunan, China.ORCID 0009-0007-4810-0392
Linshuang LiDepartment of Gynecology and Obstetrics, Changsha Central Hospital of University of South China, Changsha, Hunan, China.ORCID 0009-0004-7885-6762
Xin WeiDepartment of Gynecology and Obstetrics, Changsha Central Hospital of University of South China, Changsha, Hunan, China.ORCID 0009-0003-6115-0213
Minghua LiDepartment of Gynecology and Obstetrics, Changsha Central Hospital of University of South China, Changsha, Hunan, China.ORCID 0009-0002-3005-6489

Funding

Natural Science Foundation of Hunan Province 2023JJ40073Natural Science Foundation of Hunan Province 2026JJ82018Natural Science Foundation of Hunan Province 2026JJ82241
6 · The paper itself

Abstract

High-grade serous ovarian cancer (HGSOC) exhibits homologous recombination deficiency (HRD), but its impact on the immune microenvironment remains unclear. Using single-cell RNA sequencing, spatial transcriptomic inference, and survival analyses, we characterized 166,895 macrophages across HRD subtypes: functional BRCA1/2 inactivation (FBI), HRD-Del (deletions), and HRD-Dup (duplications). FBI macrophages showed lipid metabolism enrichment (S100A8, CD36), HRD-Del macrophages upregulated antigen presentation (HLA-DQA1, HLA-DPB1), and HRD-Dup macrophages displayed interferon-stimulated gene expression (ISG15, MX1). Six macrophage subtypes (C1Q, FCN1, MARCO, MKI67, MMP9, S100A9) exhibited distinct spatial distributions and functions. MKI67+ macrophages correlated with improved survival, while C1Q + subsets predicted worse outcomes. HRD-Dup tumors with high macrophage signatures had better survival, suggesting a favorable immune landscape. Our findings reveal HRD-driven macrophage reprogramming as a key determinant of immune microenvironment composition and clinical outcomes, supporting HRD-specific macrophage-targeted therapies for HGSOC.

Indexed as

Cystadenocarcinoma, SerousHomologous RecombinationMacrophagesOvarian NeoplasmsFemaleGene Expression Regulation, NeoplasticHumansNeoplasm GradingTumor Microenvironmenthigh-grade serous ovarian cancer (HGSOC)homologous recombination deficiency (HRD)macrophage reprogrammingtumor immune microenvironment

Identifiers

PMID42106020
PMCPMC13157315

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.